^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Salivary Gland Cancer
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ESMO Open
    Title:

    Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

    Published date:
    03/12/2021
    Excerpt:
    Patients were enrolled at five dose levels using 100 mg of VAN orally daily and 2.5 mg of EV orally daily for 28 days as starting doses…Another patient with metastatic salivary duct carcinoma harboring a PIK3CA H1047R mutation experienced a 33% reduction in tumor size compared with baseline and received a total of 12 cycles...
    Secondary therapy:
    everolimus
    DOI:
    10.1016/j.esmoop.2021.100079